Endocrine Abstracts (2017) 49 EP1372 | DOI: 10.1530/endoabs.49.EP1372

20,000 euros for diagnosis of one thyroid cancer case: It is not too much?

Marek Maciejewski1, Agnieszka Sawicka1, Michal Slomian1, Malgorzata Gasiorek1, Renata Budzynska-Nosal1 & Krzysztof Marczewski1,2


1Pope John Paul II Regional Hospital, Zamosc, Poland; 2University of Economy and Innovation, Lublin, Poland.


Introduction: Thyroid cancer is a major public health problem, and fine-needle biopsy is an established method of its early detection. However, there are still some controversy about the indication for BACC depending on the clinical data and the results of diagnostic imaging. An important role is also played by economic criteria, including socially acceptable, so-called equitable cost of obtaining additional year of life, which in our country is determined to three times the average national income per capita.

Results: We analyzed the results of fine needle biopsy of thyroid nodules taken in the years 2008–2016 in ambulatory patients. In most cases, these people were targeted due to changes in the ultrasound detected by examination performed for other indications, the so-called incidentalomas. The most common indication was evaluating the patency of the carotid arteries. We have performed total of 5347 biopsy of thyroid focal lesions which led to the diagnosis of eight cases of thyroid cancer. Average cost detection of a single cancer case amounted to approximately 20 000 Euro.

Conclusion: This cost does not exceed three times the annual GDP per capita, but is high. Therefore, it seems reasonable to discuss the criteria for performing the BACC in case of incidental thyroid focal changes, particularly in regions with a lower incidence of thyroid cancer.

Article tools

My recent searches

No recent searches.